Table 4_KRASG12C inhibitors versus chemotherapy alone for KRASG12C-mutated non-small cell

A pooled meta-analysis of two phase 3 randomized controlled trials evaluating KRASG12C inhibitors versus chemotherapy for non-small cell lung cancer. The analysis includes data from 798 patients and reports on progression-free survival, central nervous system progression-free survival, objective response rates, and treatment-related adverse events. Author Shuang Liang published the results on figshare under a CC-BY-4.0 license in April 2026.

Use Cases

• Compare progression-free survival (PFS) between treatment groups based on hazard ratios
• Analyze central nervous system (CNS) progression-free survival outcomes based on reported HR
• Evaluate objective response rate (ORR) and disease control rate (DCR) differences between therapies
• Assess treatment-related adverse event (TRAE) profiles, including grade 3–5 events
• Conduct subgroup analyses for PFS benefit across predefined patient subgroups

Strengths

• Data originates from two phase 3 randomized controlled trials (CodeBreaK 200 and KRYSTAL-12), a high-quality source
• Analysis includes 798 patients, providing a substantial sample size for meta-analysis
• Reports specific hazard ratios (e.g., PFS HR: 0.62) and response rate ratios (e.g., ORR RR: 2.73) with confidence intervals
• Lists top grade 3–5 adverse events with precise percentages (e.g., diarrhea 7.63%)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is a 70.0 KB DOC file, suggesting limited raw data scope, likely containing summary tables

Provenance

Source

Pooled analysis from CodeBreaK 200 and KRYSTAL-12 clinical trials

Collection Method

Systematic literature search and meta-analysis of phase 3 RCTs

Freshness

Last updated 2026-04-15 05:47:43